B · Normal
On September 18, Xenon Pharmaceuticals’ U.S. stocks fell more than 28% before the market opened because the company suspended the recruitment of new patients in its depression drug trial.
Related telegraphs
On September 22, research firm MoffettNathanson lowered AT&T’s target price from
09-22 18:49
[Nvidia’s price-to-earnings ratio has dropped to its lowest level in more than a
09-22 18:49
On September 22, Oppenheimer raised Microsoft’s target price from $515 to $570.
09-22 18:34
[Analyst: The moat of personal intelligence far exceeds that of chatbots. OpenAI
09-22 17:56
[Coherent launches integrated optical platform for AI infrastructure and is expe
09-22 17:21
[Well-known investor: The S&P 500 is expected to first rise above 8,000 points b
09-22 17:16
Comments